Developmentally regulated GTP binding protein 2 (DRG2)

Developmentally regulated GTP binding protein 2 (DRG2) is a highly conserved GTPase of the TRAFAC class within the OBG family, functioning as an intracellular signaling protein that hydrolyzes GTP[1][3][5]. DRG2 acts as a multifaceted regulator of diverse cellular processes, including progression through the G2/M phase of the cell cycle by modulating the cyclin B1/Cdk1 complex, intracellular trafficking via Rab5 deactivation and transferrin recycling, stabilization of endosomal membrane tubules through Rac1-dependent interactions, and orchestration of microtubule dynamics essential for spindle formation, cell migration, and Golgi organization[1][3]. It also maintains mitochondrial homeostasis by regulating Drp1 expression, impacting mitochondrial morphology, energetics, and apoptosis sensitivity[1]. In the central nervous system, DRG2 plays a role in dopamine release, with knockout models displaying motor dysfunctions reversible by L-DOPA[1]. In cancer, DRG2 levels influence response to chemotherapeutic agents and may contribute to metastasis and drug resistance[1][3]. Genetically, DRG2 is located within the Smith-Magenis syndrome region and is associated with several congenital syndromes[5]. Despite wide expression and evolutionary conservation, no drugs are currently approved that directly target DRG2, though it modulates cellular sensitivity to microtubule-interacting agents[1][3][5].

Other names

DRG2DRG-2TRAFAC GTPase DRG2Translation factor GTPase DRG2developmentally-regulated GTP-binding protein 2

While no drugs are specifically targeted at DRG2, alterations in DRG2 expression change cell sensitivity to microtubule inhibitors; DRG2 overexpression or depletion affects microtubule dynamics, cell cycle arrest, and apoptosis in the presence of these drugs[1][3].